Overview

Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD

Status:
Not yet recruiting
Trial end date:
2024-03-31
Target enrollment:
Participant gender:
Summary
this study will compare the efficacy and safety of HLX04-O administered by IVT with ranibizumab in patients with active CNV secondary to AMD.
Phase:
Phase 3
Details
Lead Sponsor:
Shanghai Henlius Biotech
Treatments:
Antibodies
Antibodies, Monoclonal
Endothelial Growth Factors
Mitogens
Ranibizumab